For: | Zhou Q, Yan XF, Pan WS, Zeng S. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? World J Gastroenterol 2008; 14(16): 2617-2619 [PMID: 18442220 DOI: 10.3748/wjg.14.2617] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i16/2617.htm |
Number | Citing Articles |
1 |
Elżbieta Wojaczyńska, Jacek Wojaczyński. Sulfoxides in medicine. Current Opinion in Chemical Biology 2023; 76: 102340 doi: 10.1016/j.cbpa.2023.102340
|
2 |
David Armstrong, Daniel Sifrim. New Pharmacologic Approaches in Gastroesophageal Reflux Disease. Thoracic Surgery Clinics 2011; 21(4): 557 doi: 10.1016/j.thorsurg.2011.09.005
|
3 |
Yuhong Yuan, Richard H Hunt. Evolving issues in the management of reflux disease?. Current Opinion in Gastroenterology 2009; 25(4): 342 doi: 10.1097/MOG.0b013e32832c1504
|
4 |
Anurag T. K. Baidya, Bhanuranjan Das, Bharti Devi, Bengt Långström, Hans Ågren, Taher Darreh-Shori, Rajnish Kumar. Mechanistic Insight into the Inhibition of Choline Acetyltransferase by Proton Pump Inhibitors. ACS Chemical Neuroscience 2023; 14(4): 749 doi: 10.1021/acschemneuro.2c00738
|
5 |
Yu Kyung Cho, Myung-Gyu Choi, Hyojin Park, Ji Won Kim, Dong Ho Lee, Kwang Hyun Ko, Sang Gyun Kim, Hwoon-Yong Jung, Su Jin Hong, Yong Chan Lee, Si Hyung Lee. Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial. Journal of Neurogastroenterology and Motility 2021; 27(2): 223 doi: 10.5056/jnm19053
|
6 |
Shuchi Dixit, Rituraj Dubey, Ravi Bhushan. Normal and polar‐organic‐phase high‐performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro‐methylated cellulose‐based chiral stationary phase and determination of dexrabeprazole. Biomedical Chromatography 2014; 28(1): 112 doi: 10.1002/bmc.2915
|
7 |
Usha Dutta, Yuhong Yuan, Paul Moayyedi, Grigorios I Leontiadis. High dose versus standard dose proton pump inhibitor for short term management of erosive reflux oesophagitis. Cochrane Database of Systematic Reviews 2013; doi: 10.1002/14651858.CD010581
|
8 |
Sachin Mane. Racemic drug resolution: a comprehensive guide. Analytical Methods 2016; 8(42): 7567 doi: 10.1039/C6AY02015A
|
9 |
Vasundhara Tolia. Esomeprazole Use in Pediatrics. Pediatric Health 2008; 2(6): 687 doi: 10.2217/17455111.2.6.687
|
10 |
Michael E. El-Kommos, Pakinaz Y. Khashaba, Hassan Refat H. Ali, Mohamed M. El-Wekil. Different Chromatographic and Electrophoretic Methods for Analysis of Proton Pump Inhibitors (PPIs): A Review. Journal of Liquid Chromatography & Related Technologies 2015; 38(18): 1639 doi: 10.1080/10826076.2015.1079722
|
11 |
Gergely Dombi, Levente Tyukodi, Máté Dobó, Gergely Molnár, Zsuzsanna Rozmer, Zoltán-István Szabó, Béla Fiser, Gergő Tóth. Enantioselective Binding of Proton Pump Inhibitors to Alpha1-Acid Glycoprotein and Human Serum Albumin—A Chromatographic, Spectroscopic, and In Silico Study. International Journal of Molecular Sciences 2024; 25(19): 10575 doi: 10.3390/ijms251910575
|
12 |
Roberto Cirilli, Rosella Ferretti, Bruno Gallinella, Luciana Turchetto, Leo Zanitti, Francesco La Torre. Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(−)-lansoprazole enantiomers and related impurities. Journal of Pharmaceutical and Biomedical Analysis 2009; 50(1): 9 doi: 10.1016/j.jpba.2009.03.021
|
13 |
David Armstrong, Daniel Sifrim. New Pharmacologic Approaches in Gastroesophageal Reflux Disease. Gastroenterology Clinics of North America 2010; 39(3): 393 doi: 10.1016/j.gtc.2010.08.019
|
14 |
Chongzhuang Tang, Zhaoqiang Chen, Xiaojian Dai, Weiliang Zhu, Dafang Zhong, Xiaoyan Chen. Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors. Drug Metabolism and Disposition 2019; 47(6): 657 doi: 10.1124/dmd.118.086090
|
15 |
Neriman Ipek KIRMIZI SONMEZ, Caner VIZDIKLAR, Volkan AYDIN, Onur GULTEKIN, Ayfer BAHAR, Ahmet AKICI. The impact of chiral switch on drug labeling in Turkey: indication, posology, and adverse effects. Marmara Medical Journal 2023; 36(3): 351 doi: 10.5472/marumj.1368074
|
16 |
Tae Jin Lee, Dohyun Kim, Jae Cheon Kim, Si Won Ro, Dong Hee Na. Formulation development and pharmacokinetic evaluation of enteric-coated dexrabeprazole tablets. Journal of Pharmaceutical Investigation 2023; 53(2): 323 doi: 10.1007/s40005-022-00602-x
|
17 |
Linda Luo, Xiaoli Wen, Yueying Du, Zhen Jiang, Xingjie Guo. Enantioselective analysis of lansoprazole in rat plasma by LC–MS/MS: Application to a stereoselective pharmacokinetic study. Biomedical Chromatography 2018; 32(11) doi: 10.1002/bmc.4345
|